The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Intervacc to participate at ABGSC Investor Day on September 7
On Monday, September 7, Intervacc’s CEO Andreas Andersson will participate in the live broadcast of ABGSC Investor Day in Stockholm. The company is in an exciting and intensive phase with, among other things, an ongoing process for a European granting of a...Intervacc has carried out a directed issue of approximately 6.5 million shares, raising gross proceeds of approximately SEK 147 million
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION,...Intervacc intends to carry out a directed share issue
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE , IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION,...Intervacc and the Karolinska Institutet extend contract for the development of innovative animal health vaccines
Stockholm 15 June 2020 – Intervacc AB (publ) and the Karolinska Institute, KI, announce today that they have extended the contract for the development of a new generation of animal health vaccines using recombinant proteins. The extended contract means that the...Nyhetstjänster
